Skip to main content

Outage notice:

Due to the global information outage that occurred Friday, Quest is taking swift action to respond, recover and restore our operations. Our Patient Services are operating with reduced capacity so you may experience longer wait and service times. Our Customer Contact teams are currently unavailable. We appreciate your patience as we work toward returning to normal operations. 


Monitor chronic kidney disease with confidence

Chronic kidney disease (CKD) due to diabetes occurs in 20 to 40% of patients and is the most common cause of end-stage renal disease.1

Quest Diagnostics’ Diabetes, Advancing CKD Management Panel provides you with a way to offer comprehensive annual testing to diabetes patients who may be at risk for CKD or who have progressed to stage 3 or 4 CKD.

Learn more about the Diabetes, Advancing CKD Management Panel

Learn more about guideline-based testing for CKD

Nonalcoholic fatty liver disease

The Nonalcoholic Fatty Liver Disease (NAFLD) Score Panel identifies diabetes patients who are at risk for developing serious liver disease. A complete fibrosis score is calculated and provided at no additional cost.

Associated risk tests

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.


  1. CDC. Chronic kidney disease in the United States, 2021. Last reviewed March 4, 2021. Accessed April 2, 2021.